Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease
dc.contributor.author | Subramaniam, Kavitha | |
dc.contributor.author | Fallon, Kieran | |
dc.contributor.author | Ruut, Tom | |
dc.contributor.author | Lane, D | |
dc.contributor.author | McKay, R. | |
dc.contributor.author | Shadbolt, Bruce | |
dc.contributor.author | Ang, S. | |
dc.contributor.author | Cook, Matthew | |
dc.contributor.author | Platten, J. | |
dc.contributor.author | Pavli, Paul | |
dc.contributor.author | Taupin, Douglas | |
dc.date.accessioned | 2019-07-25T01:52:10Z | |
dc.date.issued | 2015 | |
dc.date.updated | 2019-03-31T07:21:46Z | |
dc.description.abstract | Background Muscle wasting or sarcopenia arising from chronic inflammation is found in 60% of patients with Crohn's disease. Transcriptional protein NF-κB reduces muscle formation through MyoD transcription and increases muscle breakdown by proteolysis. Aim As TNF is a potent activator of NF-κB, and anti-TNF agent infliximab (IFX) prevents NF-κB activation, to determine whether or not Crohn's patients treated with IFX gain muscle volume and strength. Methods We performed a prospective, repeated-measures cohort study in adult Crohn's disease patients with an acute disease flare. Patients were instructed not to vary diet or activity. Concomitant medications were kept stable. At week 1 (pre-treatment), week 16 (post-IFX induction) and week 25 (post-first IFX maintenance dose), we assessed (i) MRI volume of quadriceps femoris at anatomical mid-thigh; (ii) maximal concentric quadriceps contractions strength at three specific speeds of contraction; (iii) physical activity by validated instrument (IPAQ); (iv) Three-day food record of intake and composition (food-weighing method); (v) Serum levels of IL6. Results Nineteen patients (58% female; mean age 33.2 ± 10.7 years) were recruited. IFX increased muscle volume in both legs from baseline (right, 1505 cm3) to week 25 (right, 1569 cm3; P = 0.010). IFX also increased muscle strength in both legs from baseline (right 30°/s, 184.8 Nm) to week 25 (right 30°/s, 213.6 Nm; P = 0.002). Muscle volume gain correlated with male gender (P = 0.003). Significant gains in muscle volume and strength were unrelated to prednisolone use. Serum IL6 levels decreased by week 25 (P = 0.037). Conclusion The anti-TNF agent infliximab reverses inflammatory sarcopenia in patients with Crohn's disease. | en_AU |
dc.description.sponsorship | The project was funded entirely by the Canberra Hospital Private Practice Trust Fund. | en_AU |
dc.format.mimetype | application/pdf | en_AU |
dc.identifier.issn | 0269-2813 | en_AU |
dc.identifier.uri | http://hdl.handle.net/1885/164703 | |
dc.language.iso | en_AU | en_AU |
dc.publisher | Wiley-Blackwell | en_AU |
dc.rights | © 2015 John Wiley & Sons Ltd | en_AU |
dc.source | Alimentary pharmacology & therapeutics | en_AU |
dc.subject | C reactive protein | en_AU |
dc.subject | immunomodulating agent | en_AU |
dc.subject | infliximab | en_AU |
dc.subject | interleukin 6 | en_AU |
dc.subject | mesalazine | en_AU |
dc.subject | prednisolone | en_AU |
dc.subject | autacoid | en_AU |
dc.subject | immunoglobulin enhancer binding protein | en_AU |
dc.subject | infliximab | en_AU |
dc.subject | monoclonal antibody | en_AU |
dc.subject | tumor necrosis factor alpha | en_AU |
dc.subject | acute disease | en_AU |
dc.subject | adult | en_AU |
dc.subject | aged | en_AU |
dc.subject | Article | en_AU |
dc.subject | caloric | en_AU |
dc.title | Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease | en_AU |
dc.type | Journal article | en_AU |
local.bibliographicCitation.issue | 5 | en_AU |
local.bibliographicCitation.lastpage | 428 | en_AU |
local.bibliographicCitation.startpage | 419 | en_AU |
local.contributor.affiliation | Subramaniam, Kavitha, College of Health and Medicine, ANU | en_AU |
local.contributor.affiliation | Fallon, Kieran, College of Health and Medicine, ANU | en_AU |
local.contributor.affiliation | Ruut, Tom, College of Health and Medicine, ANU | en_AU |
local.contributor.affiliation | Lane, D, Department of Imaging | en_AU |
local.contributor.affiliation | McKay, R., Department of Imaging | en_AU |
local.contributor.affiliation | Shadbolt, Bruce, College of Health and Medicine, ANU | en_AU |
local.contributor.affiliation | Ang, S., Cancer Research | en_AU |
local.contributor.affiliation | Cook, Matthew, College of Health and Medicine, ANU | en_AU |
local.contributor.affiliation | Platten, J., Gastroenterology and Hepatology Unit | en_AU |
local.contributor.affiliation | Pavli, Paul, College of Health and Medicine, ANU | en_AU |
local.contributor.affiliation | Taupin, Douglas, College of Health and Medicine, ANU | en_AU |
local.contributor.authoremail | u1814247@anu.edu.au | en_AU |
local.contributor.authoruid | Subramaniam, Kavitha, u5430653 | en_AU |
local.contributor.authoruid | Fallon, Kieran, u4140859 | en_AU |
local.contributor.authoruid | Ruut, Tom, u4234516 | en_AU |
local.contributor.authoruid | Shadbolt, Bruce, u1814247 | en_AU |
local.contributor.authoruid | Cook, Matthew, u2572788 | en_AU |
local.contributor.authoruid | Pavli, Paul, u3683784 | en_AU |
local.contributor.authoruid | Taupin, Douglas, u3510029 | en_AU |
local.description.embargo | 2037-12-31 | |
local.description.notes | Imported from ARIES | en_AU |
local.identifier.absfor | 110307 - Gastroenterology and Hepatology | en_AU |
local.identifier.ariespublication | u4425841xPUB83 | en_AU |
local.identifier.citationvolume | 41 | en_AU |
local.identifier.doi | 10.1111/apt.13058 | en_AU |
local.identifier.scopusID | 2-s2.0-84921917087 | |
local.identifier.thomsonID | 000348731400002 | |
local.identifier.uidSubmittedBy | u4425841 | en_AU |
local.publisher.url | https://www.wiley.com/en-gb | en_AU |
local.type.status | Published Version | en_AU |
Downloads
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- 01_Subramaniam_Infliximab_reverses_2015.pdf
- Size:
- 482.77 KB
- Format:
- Adobe Portable Document Format